RetinAI
Expediting Drug Discovery and Development

Every year, pharmaceutical and life sciences companies make significant investments in ophthalmological drug discovery. To overcome challenges associated with the long and risky timeline of clinical studies, they need to make quick and informed or data-driven decisions from the initial stages of drug development. Data that helps scientists determine the drug’s probability of success is of utmost importance to back up and bring confidence to these decisions.

RetinAI, through its FDA approved cloud-based data management platform, RetinAI Discovery^®, combines the power of data management, enrichment, and process automation to present scientists with actionable data and enhanced insights for making accelerated decisions with data-driven confidence. It ultimately brings therapeutics to market by fast-tracking the drug discovery process.

“The RetinAI Discovery platform is an all-encompassing, connected software solution that centralizes data and workflows to a single ecosystem for a more time and cost-efficient approach to developing ophthalmological drugs,” says Dr Carlos Ciller, co-founder and CEO of RetinAI.

RetinAI Discovery^® helps pharmaceutical and life science companies collect and manage data from ongoing and past clinical studies providing a high degree of transparency and the ability for detailed evaluations between studies and real world evidence. It allows scientists to aggregate and harmonize the data in a manner that enables them to better understand patient outcomes, subgroup identification, and overall drug impact.

Defining these endpoints gives them an idea of the expected results in the following study phases. If determined unsuccessful after a detailed, targeted data analysis of patients, scientists can withdraw resources invested in the study, saving time and money and redirect resources to other patient subgroups to study, based on the analysis.

Powering the cutting-edge platform is a set of certified AI models built on use cases in the ophthalmology space. The models extract critical, actionable insights from organized data, including the rate at which a patient is recovering through visualization and analysis of progression analytics.

It enables scientists to quickly determine the course of drug development while eliminating uncertainty from the entire process.

The advantages of RetinAI’s Discovery^® are also made available to doctors to help them better treat patients diagnosed with ophthalmological diseases. Its AI technology covers screening, quantifying, and assessing the severity of a specific disease to predict patient progression with and without treatment. It helps doctors design disease-specific treatments or alter the course of existing ones.

In one instance, a group of clinics in a European country adopted RetinAI Discovery^® to detect the presence of a biomarker linked to the development of a particular disease. Discovery^® helped the doctors identify its existence, enabling them to modify and enhance the treatment plan for patients.

The RetinAI Discovery platform is an all-encompassing, connected software solution that centralizes data and workflows to a single ecosystem for a more time and cost-efficient approach to developing ophthalmological drugs

Apart from its state-of-the-art platform, RetinAI offers Disease Evaluation Applications based on AI for doctors that are integrated into medical devices. These Apps can be currently accessed through the Heidelberg Engineering Appway in their Heyex 2 platform, allowing doctors to benefit from the in-depth analysis of anatomical features on OCT to help patient management.

It processes the data with AI algorithms and provides a comprehensive report at the patient’s visit. The results offer a comprehensive analysis of the retinal biomarkers and volumetric measures of fluid and layer thickness for diseases that help doctors formulate better treatment management strategies, especially in vision-threatening conditions.

Stakeholders across pharma and life sciences are always allowed to try and test RetinAI’s solutions before implementing them. For instance, RetinAI offers Discovery to pharmaceutical companies as a time-bound, small pilot solution that can be extended after successful trial. Physicians or researchers can also try RetinAI’s tailored solution for academic and clinical research, Discovery CORE, for free for the first two months.

Numerous research centers and hospitals in the U.S. and Europe are using the platform to bring life-changing drugs to the market faster. Through its one-of-a-kind platform, RetinAI is redefining the standard practice of drug development in ophthalmology, from clinical studies to commercialization.